Skip to main content

Table 1 Clinical and serological features of patients by study group

From: Presence of antibodies against cyclic citrullinated peptides in patients with 'rhupus': a cross-sectional study

Characteristics

Rhupus

RA

SLE

Controls

Number of patients

7

7

7

7

Median age, years (range)

44 (25–64)

46 (31–61)

41 (24–66)

41 (28–63)

Median age of onset, years (range)

26 (11–61)

40 (27–45)

39 (18–52)

-

SLE criteria, n (percentage)

    

   Malar rash

5 (71)

-

7 (100)

-

   Discoid lupus

1 (14)

-

1 (14)

-

   Photosensitivity

4 (57)

-

5 (71)

-

   Oral ulcers

5 (71)

-

5 (71)

-

   Serositis

3 (43)

-

0 (0)

-

   Renal

2 (29)

-

2 (29)

-

   Neurological

1 (14)

-

1 (14)

-

   Hematological

7 (100)

-

6 (86)

-

   Immunological

4 (57)

-

5 (71)

-

   ANA

7 (100)

-

7 (100)

-

RA criteria, n (percentage)

    

   Morning stiffness

3 (43)

5 (71)

-

-

   Arthritis in more than three areas

7 (100)

7 (100)

-

-

   Arthritis of hands

7 (100)

7 (100)

-

-

   Symmetric arthritis

7 (100)

7 (100)

-

-

   Rheumatoid nodules

0 (0)

3 (43)

-

-

   RF

5 (71)

6 (86)

-

-

   X-ray changes

7 (100)

7 (100)

-

-

Serology, n (percentage)

    

   Anti-CCP

4 (57)

6 (86)

0 (0)

0 (0)

   ANA

7 (100)

0 (0)

7 (100)

2 (29)

   Anti-dsDNA

4 (57)

0 (0)

4 (57)

0 (0)

   Anti-SSA

4 (57)

0 (0)

3 (43)

1 (14)

   Anti-SSB

1 (14)

0 (0)

1 (14)

0 (0)

   Anti-Sm

1 (14)

0 (0)

2 (29)

0 (0)

   Anti-RNP

1 (14)

0 (0)

2 (29)

0 (0)

   RF

5 (71)

6 (86)

2 (29)

1 (14)

  1. ANA, antinuclear antibodies; anti-CCP, antibodies against cyclic citrullinated peptides; anti-dsDNA, antibodies against double-stranded DNA; anti-RNP, antibodies against ribonucleoprotein; RA, rheumatoid arthritis; RF, rheumatoid factor; SLE, systemic lupus erythematosus; SS, Sjögren's syndrome.